Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,172,746
  • Shares Outstanding, K 95,185
  • Annual Sales, $ 31,430 K
  • Annual Income, $ -173,390 K
  • 60-Month Beta 1.63
  • Price/Sales 208.51
  • Price/Cash Flow N/A
  • Price/Book 9.13
Trade FATE with:

Options Overview Details

View History
  • Implied Volatility 69.38%
  • Historical Volatility 50.65%
  • IV Percentile 17%
  • IV Rank 15.44%
  • IV High 125.26% on 11/13/20
  • IV Low 59.17% on 06/14/21
  • Put/Call Vol Ratio 0.06
  • Today's Volume 545
  • Volume Avg (30-Day) 275
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 129
  • Open Int (30-Day) 174

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.58
  • Number of Estimates 10
  • High Estimate -0.41
  • Low Estimate -0.65
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -61.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.35 +3.22%
on 09/27/21
76.42 -15.78%
on 09/02/21
-8.28 (-11.40%)
since 08/27/21
3-Month
62.35 +3.22%
on 09/27/21
97.43 -33.94%
on 08/10/21
-20.19 (-23.88%)
since 06/25/21
52-Week
37.89 +69.86%
on 09/28/20
121.16 -46.88%
on 01/14/21
+26.56 (+70.26%)
since 09/25/20

Most Recent Stories

More News
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication...

FATE : 64.36 (-0.76%)
2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40%

Cathie Wood has won investors’ confidence with her funds’ significant gains last year. The renowned investor believes that investing in innovation is the key to success. And Wall Street analysts are...

Z : 90.47 (+0.07%)
FATE : 64.36 (-0.76%)
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab...

FATE : 64.36 (-0.76%)
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

FATE reports a wider loss on increased R&D expenses in the second quarter.

BMY : 59.84 (-0.65%)
JNJ : 163.17 (-0.72%)
GILD : 70.41 (-1.10%)
FATE : 64.36 (-0.76%)
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -11.54% and 89.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

FATE : 64.36 (-0.76%)
Fate Therapeutics: Q2 Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $55.1 million in its second quarter.

FATE : 64.36 (-0.76%)
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal Master...

FATE : 64.36 (-0.76%)
Fate Therapeutics Appoints Yuan Xu to its Board of Directors

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan...

FATE : 64.36 (-0.76%)
AKRO : 24.04 (+1.31%)
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

FATE : 64.36 (-0.76%)
Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FATE : 64.36 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 68.76
2nd Resistance Point 67.07
1st Resistance Point 65.72
Last Price 64.36
1st Support Level 62.68
2nd Support Level 60.99
3rd Support Level 59.64

See More

52-Week High 121.16
Fibonacci 61.8% 89.35
Fibonacci 50% 79.53
Fibonacci 38.2% 69.70
Last Price 64.36
52-Week Low 37.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar